Novartis AG 2026 Q1 - Results - Earnings Call Presentation
Novartis AG reported first-quarter 2026 earnings with revenue of $13.52 billion, a 0.7% year-over-year decline but $43.88 million above estimates, while earnings per share of $1.99 missed expectations by $0.08. The company highlighted performance across key therapeutic areas and reaffirmed its full-year financial guidance. Operational execution remained strong despite foreign exchange headwinds. Management emphasized progress in pipeline development and cost efficiency initiatives.
- ▪Novartis AG reported Q1 2026 revenue of $13.52 billion, down 0.7% year-over-year but $43.88 million above analyst expectations.
- ▪Earnings per share for the quarter were $1.99, missing estimates by $0.08.
- ▪The company maintained its full-year 2026 financial guidance despite currency pressures.
- ▪Key growth drivers included performance in cardiovascular and radioligand therapies.
- ▪Novartis reaffirmed its focus on innovation, cost optimization, and shareholder returns.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895008-novartis-ag-2026-q1-results-earnings-call-presentation"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
